Abstract: Methods and materials for measuring semm elafin levels, elevated levels of which have been confirmed to detect the presence of stricture in patients with Crohn's disease (CD), and a method for improving the accuracy of detecting the presence of stricture through the use of an algorithm developed through machine learning and/or through the use of clinical data. Further, materials and methods for treating intestinal stricture in a subject having Crohn's disease, as well as for inhibiting intestinal fibrosis, inflammatory bowel disease (IBD), metabolic disease, or obesity in a subject, comprises administering elafin to the subject.

Abstract: This application discloses methods of treating, preventing, and diagnosing colorectal cancer and IBD in a subject comprising administering an effective dose of antisense miR-133? or AFTPH to the subject or detecting expression levels of miR-133? and AFTPH.

Abstract: Method of diagnosing and treating inflammatory bowel disease are disclosed herein. Inflammatory bowel disease can be treated and diagnosed using cathelicidin peptides and detection agents thereof. Specifically, method of treating and diagnosing Crohn's disease and ulcerative colitis are disclosed herein.

Abstract: Method of diagnosing and treating inflammatory bowel disease are disclosed herein. Inflammatory bowel disease can be treated and diagnosed using cathelicidin peptides and detection agents thereof. Specifically, method of treating and diagnosing Crohn's disease and ulcerative colitis are disclosed herein.

Abstract: This application discloses methods of treating, preventing, and diagnosing colorectal cancer and IBD in a subject comprising administering an effective dose of antisense miR-133? or AFTPH to the subject or detecting expression levels of miR-133? and AFTPH.

Abstract: Method of diagnosing and treating inflammatory bowel disease are disclosed herein. Inflammatory bowel disease can be treated and diagnosed using cathelicidin peptides and detection agents thereof. Specifically, method of treating and diagnosing Crohn's disease and ulcerative colitis are disclosed herein.

Abstract: This application discloses methods of treating, preventing, and diagnosing colorectal cancer and IBD in a subject comprising administering an effective dose of antisense miR-133? or AFTPH to the subject or detecting expression levels of miR-133? and AFTPH.

Abstract: Disclosed herein are methods for treating an inflammatory condition in a patient comprising administering an agent that inhibits the signaling activity of MCH, thereby inhibiting the inflammatory response in the tissue, and in a mammal comprising administering to the mammal an effective amount of an agent that inhibits MCH activity, MCH binding to an MCH receptor or the signaling activity of an MCH receptor that mediates intestinal inflammation.

Abstract: Methods for treating intestinal inflammation or ghrelin-mediated inflammation by inhibiting the activity of ghrelin or its receptor are described. Also described are methods for identifying ghrelin antagonists and ghrelin receptor antagonists.

Abstract: Methods for treating intestinal inflammation by inhibiting Clostridium difficile toxin B-mediated activation of the epidermal growth factor receptor or by inhibiting Clostridium difficile toxin B-mediated activation of the extracellular signal-regulated kinase 1/2 are described.

Abstract: The invention features a novel soluble anti-inflammatory factor (SAIF), methods of SAIF production and purification, and methods of using SAIF for the treatment or prevention of an inflammatory disease or disorder.

Abstract: Methods for treating intestinal inflammation by inhibiting the activity of leptin or its receptor are described.